BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 20015880)

  • 21. More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.
    López-Nieva P; González-Sánchez L; Cobos-Fernández MÁ; Córdoba R; Santos J; Fernández-Piqueras J
    Oncologist; 2021 Feb; 26(2):e298-e305. PubMed ID: 33191568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
    De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
    Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Murine Pten(-/-) T-ALL requires non-redundant PI3K/mTOR and DLL4/Notch1 signals for maintenance and γc/TCR signals for thymic exit.
    Hagenbeek TJ; Wu X; Choy L; Sanchez-Irizarry C; Seshagiri S; Stinson J; Siebel CW; Spits H
    Cancer Lett; 2014 May; 346(2):237-48. PubMed ID: 24384093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
    Knoechel B; Roderick JE; Williamson KE; Zhu J; Lohr JG; Cotton MJ; Gillespie SM; Fernandez D; Ku M; Wang H; Piccioni F; Silver SJ; Jain M; Pearson D; Kluk MJ; Ott CJ; Shultz LD; Brehm MA; Greiner DL; Gutierrez A; Stegmaier K; Kung AL; Root DE; Bradner JE; Aster JC; Kelliher MA; Bernstein BE
    Nat Genet; 2014 Apr; 46(4):364-70. PubMed ID: 24584072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
    Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
    Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.
    Palomero T; Sulis ML; Cortina M; Real PJ; Barnes K; Ciofani M; Caparros E; Buteau J; Brown K; Perkins SL; Bhagat G; Agarwal AM; Basso G; Castillo M; Nagase S; Cordon-Cardo C; Parsons R; Zúñiga-Pflücker JC; Dominguez M; Ferrando AA
    Nat Med; 2007 Oct; 13(10):1203-10. PubMed ID: 17873882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T-ALL: ALL a matter of Translation?
    Girardi T; De Keersmaecker K
    Haematologica; 2015 Mar; 100(3):293-5. PubMed ID: 25740104
    [No Abstract]   [Full Text] [Related]  

  • 28. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.
    Cullion K; Draheim KM; Hermance N; Tammam J; Sharma VM; Ware C; Nikov G; Krishnamoorthy V; Majumder PK; Kelliher MA
    Blood; 2009 Jun; 113(24):6172-81. PubMed ID: 19246562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
    Real PJ; Tosello V; Palomero T; Castillo M; Hernando E; de Stanchina E; Sulis ML; Barnes K; Sawai C; Homminga I; Meijerink J; Aifantis I; Basso G; Cordon-Cardo C; Ai W; Ferrando A
    Nat Med; 2009 Jan; 15(1):50-8. PubMed ID: 19098907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
    Koyama D; Kikuchi J; Hiraoka N; Wada T; Kurosawa H; Chiba S; Furukawa Y
    Leukemia; 2014 Jun; 28(6):1216-26. PubMed ID: 24301524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.
    Secchiero P; Melloni E; di Iasio MG; Tiribelli M; Rimondi E; Corallini F; Gattei V; Zauli G
    Blood; 2009 Apr; 113(18):4300-8. PubMed ID: 19190243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
    Govaerts I; Prieto C; Vandersmissen C; Gielen O; Jacobs K; Provost S; Nittner D; Maertens J; Boeckx N; De Keersmaecker K; Segers H; Cools J
    J Hematol Oncol; 2021 Jun; 14(1):97. PubMed ID: 34167562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2.
    Dovat E; Song C; Hu T; Rahman MA; Dhanyamraju PK; Klink M; Bogush D; Soliman M; Kane S; McGrath M; Ding Y; Desai D; Sharma A; Gowda C
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Down-regulation of Notch1 expression is involved in HL-60 cell growth inhibition induced by 4-hydroxynonenal, a product of lipid peroxidation.
    Pizzimenti S; Barrera G; Calzavara E; Mirandola L; Toaldo C; Dianzani MU; Comi P; Chiaramonte R
    Med Chem; 2008 Nov; 4(6):551-7. PubMed ID: 18991739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia.
    Kaushik B; Pal D; Saha S
    Curr Drug Targets; 2021; 22(15):1789-1798. PubMed ID: 33538669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia.
    Bonnet M; Loosveld M; Montpellier B; Navarro JM; Quilichini B; Picard C; Di Cristofaro J; Bagnis C; Fossat C; Hernandez L; Mamessier E; Roulland S; Morgado E; Formisano-Tréziny C; Dik WA; Langerak AW; Prebet T; Vey N; Michel G; Gabert J; Soulier J; Macintyre EA; Asnafi V; Payet-Bornet D; Nadel B
    Blood; 2011 Jun; 117(24):6650-9. PubMed ID: 21527520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Rho GTPase expression in T-ALL identifies RhoU as a target for Notch involved in T-ALL cell migration.
    Bhavsar PJ; Infante E; Khwaja A; Ridley AJ
    Oncogene; 2013 Jan; 32(2):198-208. PubMed ID: 22349824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic potential of Notch inhibition in T-cell acute lymphoblastic leukemia: rationale, caveats and promises.
    Sarmento LM; Barata JT
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1403-15. PubMed ID: 21929314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic antileukemic therapies in
    Sanchez-Martin M; Ambesi-Impiombato A; Qin Y; Herranz D; Bansal M; Girardi T; Paietta E; Tallman MS; Rowe JM; De Keersmaecker K; Califano A; Ferrando AA
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2006-2011. PubMed ID: 28174276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.
    Trinquand A; Tanguy-Schmidt A; Ben Abdelali R; Lambert J; Beldjord K; Lengliné E; De Gunzburg N; Payet-Bornet D; Lhermitte L; Mossafa H; Lhéritier V; Bond J; Huguet F; Buzyn A; Leguay T; Cahn JY; Thomas X; Chalandon Y; Delannoy A; Bonmati C; Maury S; Nadel B; Macintyre E; Ifrah N; Dombret H; Asnafi V
    J Clin Oncol; 2013 Dec; 31(34):4333-42. PubMed ID: 24166518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.